Cart
sales@molnova.com
Secukinumab B
CAS No. 1229022-83-6
Secukinumab B( —— )
Catalog No. M37701 CAS No. 1229022-83-6
Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 223 | Get Quote |
|
| 5MG | 487 | Get Quote |
|
| 10MG | 675 | Get Quote |
|
| 25MG | 1003 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSecukinumab B
-
NoteResearch use only, not for human use.
-
Brief DescriptionSecukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
-
DescriptionAnti-Human IL-17A is a fully human anti-interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1229022-83-6
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Reich K, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017 Mar;176(3):752-758. ?
molnova catalog
related products
-
Disodium clodronate ...
Clodronic acid(INN) orclodronate disodium(USAN) is a first generation (non-nitrogenous)?bisphosphonate.
-
IL-2-IN-1
IL-2-IN-1 is a potent inhibitor of IL-2 (IC50: 1978 nM) and demonstrates anti-proliferative effects.
-
Nodosin
Nodosin has an anti-inflammatory function via inhibition of IL-2. Nodosin perfusion provides a potential protective effect by inducing HO-1 expression to attenuate ischemia/reperfusion injury in liver transplantation.
